AzTrials
AzTrials

Healthy Adult ParticipantsSPARCNCT07419100

Sedentary Behaviour, Physical Activity Patterns, and Cardiometabolic Health

A study testing Continuous moderate intensity physical activity, Light-intensity physical activity breaks and High-intensity physical activity breaks in people with Healthy Adult Participants, run by Hasselt University at 1 site in Belgium.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

According to the World Health Organization (WHO), chronic diseases are a major global public health concern and the leading cause of mortality worldwide. In the absence of evidence-based actions, the global annual deaths from chronic diseases are projected to rise to 55 million deaths in 2030, accompanied by a… Read more about this study

Who is it for?
Ages 40 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Adult Participants
What is being tested?
Continuous moderate intensity physical activity, Light-intensity physical activity breaks and High-intensity physical activity breaks
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
1 siteBelgium
Study dates
1 Mar 2026to 1 Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adults aged 40-70 years
  • Sedentary (>9 hours per day)
  • < 3 exercise sessions per week

Who cannot join

  • Pregnancy or intend to become pregnant
  • Any known contra-indications for physical activity
  • >14 alcohol consumptions per week for women and >20 alcohol consumptions per week for men
  • Involved in a weight reduction program with an energy restriction diet during the study period
  • No consistent body weight over the past month
  • Diagnosed with any known cardiometabolic health-related disease

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Bert Op 't Eijnde, PhD contact

bert.opteijnde@uhasselt.be

Belgium1 site
  • Hasselt University

    Diepenbeek, Limburg, 3590

    Bert Op 't Eijnde, PhD, bert.opteijnde@uhasselt.be

    Wouter Franssen, PhD, wouter.franssen@uhasselt.be

Other trials in Belgium

About this study

Official title: From Sitting to Moving: How Physical Activity Patterns Can Reduce Sedentary Behaviour and Support Cardiometabolic Health

According to the World Health Organization (WHO), chronic diseases are a major global public health concern and the leading cause of mortality worldwide. In the absence of evidence-based actions, the global annual deaths from chronic diseases are projected to rise to 55 million deaths in 2030, accompanied by a substantial increase in socio-economic costs. In this context, the WHO identifies type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) as key chronic conditions of concern related to cardiometabolic health.

Both sedentary behaviour (SB) and physical inactivity have been recognised as interdependent risk factors for the development of T2DM and CVD. SB refers to any waking behaviour, characterised by a low energy expenditure, while being in a sitting or reclining posture, whereas physical inactivity denotes insufficient levels (<150 min per week,) of moderate-to-vigorous physical activity (MVPA). Studies using objective measures have demonstrated that on average Western adults spend 8-12h in SB per day, of which the majority is spent in prolonged sedentary bouts (lasting ≥30 min). In addition, up to 30% of adults worldwide are physically inactive, with higher levels of inactivity in high-income countries. Within this context, it has become evident that excessive prolonged SB, often in combination with physical inactivity, negatively impacts cardiometabolic health, contributing to insulin resistance, increased adiposity, poor lipid profiles and endothelial dysfunction. Given their detrimental effects on T2DM and CVD, strategies aimed at reducing SB and promoting physical activity (PA) warrant further investigation.

Read more

Reducing and regularly interrupting SB, even with low-intensity PA, alongside sufficient MVPA, is crucial for maintaining a healthy cardiometabolic profile. Reflecting this, the WHO guidelines advise individuals to engage in 150-300 minutes of moderate-intensity physical activity, 75-150 minutes of vigorous-intensity physical activity, or an equivalent combination each week. Notably, the 2020 WHO guidelines also included recommendations on SB for the first time, emphasizing the importance of limiting sedentary time. The WHO states that replacing SB with physical activity of any intensity can yield health benefits. However, these recommendations remain non-prescriptive and somewhat vague, primarily due to a lack of robust scientific evidence on the optimal frequency, intensity, and duration of PA needed to interrupt sedentary time. The absence of specific guidelines on prolonged SB reflects this evidence gap. To support policy development, well-designed randomised controlled trials are needed to evaluate effective and practical strategies for reducing sedentary time.

So far, the short term cardiometabolic health effects of SB interruptions have been investigated by our research group, laboratory studies of collaborators and other international researchers, demonstrating that; 1) more frequent SB interruptions especially affect glucose metabolism and insulin sensitivity; 2) higher intensity interruptions are associated with cardioprotective adaptations and; 3) longer durations of SB interruptions positively affect lipid metabolism. However, because under real-world conditions frequency, intensity and duration of SB interruptions usually interact, their combined effects on cardiometabolic health need further investigation. Many studies already compared the isolated effects of different SB interruption patterns with respect to frequency, duration and intensity on cardiometabolic health. However, the combined effects of these different approaches matched for energy expenditure are not clear yet. We therefore perform a balanced cross-over study in which the efficacy of distinct activity patterns on cardiometabolic health insulin sensitivity and vascular function) will be compared to a sedentary control condition.

Being tested
Continuous moderate intensity physical activity, Light-intensity physical activity breaks, High-intensity physical activity breaks
Keywords
Physical Activity, Intensity, Frequency, Duration, Cardiometabolic health
Medical subject headings
Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Continuous moderate intensity physical activityBehavioural

    One continuous physical activity bout of moderate intensity will be performed during the 6 hour testing day.

  • Light-intensity physical activity breaksBehavioural

    Light-intensity physical activity breaks every 30 minutes during the 6 hour testing day.

  • High-intensity physical activity breaksBehavioural

    High-intensity physical activity breaks every 30 minutes during the 6 hour testing day.

Study groups in NCT07419100
Study groupRoleWhat they receive
ControlNo interventionProlonged sitting for 6 hours
Continuous moderate intensity physical activityExperimentalOne continuous physical activity bout of moderate intensity will be performed during the 6 hour testing day.
Receives: Behavioral: Continuous moderate intensity physical activity
Continuous moderate intensity physical activity + light-intensity physical activity breaksExperimentalOne continuous physical activity bout of moderate intensity will be combined with light-intensity physical activity breaks every 30 minutes during the 6 hour testing day.
Receives: Behavioral: Continuous moderate intensity physical activity; Behavioral: Light-intensity physical activity breaks
Continuous moderate intensity physical activity + high-intensity physical activity breaksExperimentalOne continuous physical activity bout of moderate intensity will be combined with high-intensity physical activity breaks every 30 minutes during the 6 hour testing day.
Receives: Behavioral: Continuous moderate intensity physical activity; Behavioral: High-intensity physical activity breaks
Light-intensity physical activity breaksExperimentalProlonged sitting will be interrupted by light-intensity physical activity breaks every 30 minutes during the 6-hour testing day.
Receives: Behavioral: Light-intensity physical activity breaks
High-intensity physical activity breaksExperimentalProlonged sitting will be interrupted by high-intensity physical activity breaks every 30 minutes during the 6-hour testing day.
Receives: Behavioral: High-intensity physical activity breaks

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total and incremental area under the curve of postprandial insulin response

    Insulin concentrations will be assessed in serum samples at nine time points over the 6-hour testing period. Postprandial responses will be quantified as the area under the curve (AUC) across the six-hour period.

    Measured: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.

  2. Vascular endothelial function

    Vascular endothelial function will be assessed by flow-mediated dilation (FMD) according to published guidelines. These measurements take place at 8 a.m. and involve doppler ultrasound imaging of the superficial femoral artery. A cuff will be placed on the right lower leg, and the superficial femoral artery is imaged longitudinally. FMD will be measured at baseline and after a 5-min occlusion phase (reactive hyperaemia response). FMD will be quantified as the percentage difference between peak and baseline diameter (FMD%).

    Measured: FMD measurement will be performed at the start (08:30 a.m.) and after 6 hours (2:30 p.m.) of the testing day.

Secondary outcomes (14)
  1. Cardiorespiratory Fitness

    Cardiorespiratory fitness will be measured as peak oxygen consumption (V̇O2peak) using a graded cardiopulmonary exercise test (CPET) on a bike with pulmonary gas exchange analysis (Metalyzer IIIb) until volitional exhaustion.

    Measured: Baseline measurement

  2. Sedentary time

    Sedentary time will be quantified using the activPAL3™ activity monitor.

    Measured: Measured for 7 consecutive days after the screening visit

  3. Body mass index

    Body mass index (BMI; kg/m²) is calculated from weight and height measurements (weight/height²).

    Measured: Baseline measurement

  4. Moderate-to-vigorous physical activity

    Moderate-to-vigorous physical activity will be quantified using the activPAL3™ activity monitor.

    Measured: Measured for 7 consecutive days after the screening visit

  5. Body weight

    Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg.

    Measured: Baseline measurement

  6. High-density lipoprotein cholesterol concentration

    High-density lipoprotein cholesterol concentration will be measured in fasting plasma samples

    Measured: Blood samples will be taken at the beginning of the testing day (8 a.m.).

  7. Total cholesterol concentration

    Total cholesterol concentration will be measured in fasting plasma samples

    Measured: Blood samples will be taken at the beginning of the testing day (8 a.m.).

  8. Total and incremental area under the curve of postprandial glucose response

    Glucose concentrations will be assessed in plasma samples at nine time points over the 6-hour testing period. Postprandial responses will be quantified as the area under the curve (AUC) across the six-hour period.

    Measured: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.

  9. Total and incremental area under the curve of postprandial insulin response

    Triglyceride concentrations will be assessed in plasma samples at nine time points over the 6-hour testing period. Postprandial responses will be quantified as the area under the curve (AUC) across the six-hour period.

    Measured: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.

  10. Peak heart rate

    Peak heart rate assessed during cardiopulmonary exercise testing

    Measured: Baseline measurement

  11. Blood pressure

    After an initial resting period of 10 min with participants in a supine position in a quiet room with constant temperature (21°C), systolic and diastolic blood pressure (BP; in mmHg) will be measured at least 3 times at 2-min intervals until BP is stable using an electronic sphygmomanometer (Omron®) from the left arm and documented as the mean value of the three final measurements.

    Measured: Blood pressure will be measured during the screening visit, and hourly at 0, 60, 120, 180, 240, 300, and 360 minutes during the 6-hour testing day.

  12. Body fat percentage

    Percentage body fat will be evaluated using Dual Energy X-ray Absorptiometry.

    Measured: Baseline measurement

  13. Low-density lipoprotein cholesterol concentration

    Low-density lipoprotein cholesterol concentration will be measured in fasting plasma samples

    Measured: Blood samples will be taken at the beginning of the testing day (8 a.m.).

  14. Waist circumference

    Measured: Baseline measurement

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2026
  2. Study start1 Mar 2026 (estimated)
  3. Primary completion1 Jun 2028 (estimated)
  4. Study completion1 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Model description
Incomplete block design
Masking
None (open label)
Enrolment
48 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07419100
Sponsor's protocol ID
CME2025/100
Acronym
SPARC
Status last verified
Feb 2026
First submitted
3 Feb 2026
Last updated
18 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Continuous moderate intensity physical activity, Light-intensity physical activity breaks and High-intensity physical activity breaks in people with Healthy Adult Participants, run by Hasselt University at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Wouter Franssen, PhD (+32(0)11 29 21 29, wouter.franssen@uhasselt.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total and incremental area under the curve of postprandial insulin response (time frame: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in